Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • B. Riley raises target price from USD 65.00 to USD 70.00 with a "buy" rating.
  • Consensus rating across eight analysts is "Moderate Buy" with an average target of USD 65.33.
  • Recent brokerage updates include target adjustments by Craig Hallum, HC Wainwright, and BTIG.

Harrow (NASDAQ:HROW) operates in the healthcare sector. It provides laboratory testing, clinical services, and related solutions. The company focuses on diagnostics, personalized medicine, and laboratory services across several therapeutic areas.

Recent analyst updates show mostly positive sentiment. B. Riley raised its price target from USD 65.00 to USD 70.00 and kept a "buy" rating, implying about 42% upside from the prior close. Craig Hallum increased its target from USD 54.00 to USD 64.00 with a "buy" rating. HC Wainwright lifted its target from USD 60.00 to USD 64.00, maintaining "buy." BTIG adjusted its target from USD 62.00 to USD 63.00, also with a "buy" rating. William Blair initiated coverage with an "outperform" rating. Zacks Research downgraded its rating from "strong-buy" to "hold."

Currently, seven analysts rate the stock as Buy, and one rates it as Hold. MarketBeat reports a consensus rating of "Moderate Buy" with a target price of USD 65.33.

In its latest quarterly report dated August 11, 2025, Harrow posted EPS of USD 0.24, beating the consensus estimate of USD 0.01. Revenue reached USD 63.74 million, slightly below the expected USD 64.23 million. The company showed a negative return on equity of 2.18% and a net margin of -4.49%. Analysts expect Harrow’s full-year 2025 EPS to be -0.53.